MSB - Most exciting 6 months, page-378

My take away's from the podcast:

When refering to COVID-19 trials "in these 12 patients Using the exact same protocol as we are using for GvHD" - will allow them to apply for a label extension prior to obtaining full approval

"If the results are positive we can seek approval from the FDA for patients with acute respiratory distress syndrome" - this requires them to obtain sufficient data points, which will require sufficient patient enrollment and secondary objectives will come into play

Re-emphasises it will take 3-4 months for total patient recruitment - we're nearly 3 months in

Shorter-term focus:
- GvHD
- COVID-ARDs, then other forms of ARDs (influenza and bacterial mediated etc)
- Other acute inflammatory conditions that are life threatening, including other forms of acute inflammatory lung disease

Longer term focus:
- Cardiac-related
- Pain-related

I anticipate we won't get any positive news until next month. GLTA